Allergan, whose facial aesthetics business includes the widely used Juvederm facial filler, said it intends to complete the purchase this year and operate SkinMedica as a separate business.

Allergan said it would also pay SkinMedica an additional $25 million contingent on the acquired products hitting sales targets. The deal does not include SkinMedica's Colorescience aesthetic make-up line, Allergan said.

SkinMedica sells both prescription and non-prescription products. Its primary prescription product is Vaniqa cream, the only U.S. approved prescription product for reduction of unwanted facial hair in women.

Allergan shares rose 1 percent to $88.84 in morning trading on the New York Stock Exhhange, amid slight declines for the broad stock market.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Theodore d'Afflisio)

• A Permanent Economic Emergency